Dr. Joseph Tector, who built IU Health’s transplant program into one of the nation’s largest before announcing his departure Friday, is seeking back wages and penalties worth $4.7 million from the hospital system.
The Indiana Biosciences Research Institute, set up just three years ago, announced Wednesday morning that it has been awarded grants of $80 million from the Lilly Endowment and $20 million from the Eli Lilly and Co. Foundation.
A professor in the Indiana School of Medicine is hopeful that an antibiotic cocktail he invented will one day improve the lives of millions of people, thanks in part to the Indiana University Research and Technology Corp., formed in 1997 to make work done by IU faculty and researchers available for commercial development.
City leaders want to make the 60-acre tract of land just north of the Indiana University School of Medicine campus a mix of all of the best the city has to offer and catch the eyes of more creative and highly sought-after workers.
Researchers at the Indiana University School of Medicine found that blocking the activity of a key protein can significantly cut down on the graft-versus-host immune response suffered by large numbers of patients who receive stem cell transplants.
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.
The new head of research at the Indiana University School of Medicine thinks the institution is missing out on the more than $6 billion spent each year in the United States on clinical trials.
Michael A. Byers’ Tooth Bank is one of a tiny group of U.S. companies catering to the latest iteration of stem cell therapy: harvesting stem cells from the pulp inside baby teeth and extracted wisdom teeth, then culturing, freezing and storing them at a cryostorage facility for later use.
Dr. Keith March at the IU School of Medicine is almost like a medical superhero, churning out patents at warp speed.
Researchers at Purdue University, the Indiana University School of Medicine and the University of Wisconsin discovered a combination of two currently available drugs significantly slowed the growth of late-stage prostate cancer tumors in mice.
Terminally ill patients in Indiana who have run out of FDA-approved options can now turn to treatments and medicines in the testing phase.
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
After weathering a barrage of patent expirations, the pharmaceutical giant has restocked its pipeline and is positioned to grow.
The two companies will work together to develop AZD3293, which belongs to a novel class of drugs called BACE inhibitors that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
The drug company said Thursday its drug ixekizumab cleared away skin inflammation in six times as many patients as the blockbuster drug Enbrel. Lilly is in a race to bring the first in a new-class of psoriasis treatments to market.
Regenstrief, a not-for-profit medical research organization, plans to move 50 investigators, 165 staff members and a number of affiliated scientists into the building when it is completed in mid-2015.
Founders of Chondrial Therapeutics believe that if further testing validates their treatment for Friedreich’s ataxia, it could be a blockbuster with annual sales topping $1 billion.
Two insurers announced Tuesday that they are partnering for an ambitious project to establish one of the nation's largest health-information exchanges, an effort they hope will reduce duplication and improve patient outcomes.
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
